NeuroRx seeks emergency use authorization for its experimental Covid-19 therapy

NeuroRx said Wednesday it has submitted an emergency use authorization request with the Food and Drug Administration for the company's Covid-19 treatment in patients who have exhausted all approved treatments. NeuroRx is based in Wilmington and has its clinical operations in Radnor. The emergency use authorization would cover the use of RLF-100, which NeuroRx is developing in a partnership with Relief Therapeutic Holdings of Geneva, Switzerland. RLF-100 is a patented formulation of synthetic human…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news